Abstract
High-performance neutralizing antibody against influenza virus typically recognizes the globular head region of its hemagglutinin (HA) envelope glycoprotein. To-date, approved human vaccination strategies have been designed to induce such antibodies as a sole means of preventing the consequences of this infection. However, frequent amino-acid changes in the HA globular head allow for efficient immune evasion. Consequently, vaccines inducing such neutralizing antibodies need to be annually re-designed and re-administered at a great expense. These vaccines furthermore provide little-to-no immunity against antigenic-shift strains, which arise from complete replacement of HA or of neuraminidase genes, and pose pandemic risks. To address these issues, laboratory research has focused on inducing immunity effective against all strains, regardless of changes in the HA globular head. Despite prior dogma that such cross-protection needs to be induced by cellular immunity alone, several advances in recent years demonstrate that antibodies of other specificities are capable of cross-strain protection in mice. This review discusses the reactivity, induction, efficacy, and mechanisms of antibodies that react with poorly accessible epitopes i...Continue Reading
Citations
Jul 12, 2014·BioMed Research International·Eleonora MolestiNigel Temperton
Jan 1, 2014·Vaccines·Claudia Maria TrombettaEmanuele Montomoli
Oct 23, 2012·Vaccine·Charles NfonShawn Babiuk
Jan 1, 2013·Antiviral Research·Irina L TutykhinaAlexander L Gintsburg
Jul 19, 2015·Immunity·Jessica L HallileyF Eun-Hyung Lee
Apr 14, 2015·Nanomedicine·Anushree SethYong Taik Lim
Jan 1, 2013·Antiviral Research·Sergei V TillibAlexander L Gintsburg
Dec 21, 2016·Molecular Ecology·M WilleJ Waldenström
Apr 5, 2017·International Journal of Molecular Sciences·Ashraf Metwally, Ausama Yousif
Feb 6, 2013·Chest·Margarita M Gomez Lorenzo, Matthew J Fenton
Sep 12, 2014·Journal of Virology·Attapon KamlangdeeJorge E Osorio
Jun 14, 2013·Clinical and Vaccine Immunology : CVI·Rogier BodewesGuus F Rimmelzwaan
Oct 13, 2017·PloS One·Ahmed O HassanSuresh K Mittal
Oct 27, 2018·Expert Review of Vaccines·Ye WangBao-Zhong Wang
Feb 13, 2018·MSphere·Lisa C LindesmithRalph S Baric
Jul 14, 2012·The Journal of General Virology·Yohei WatanabeKazuyoshi Ikuta
Oct 18, 2019·Food and Environmental Virology·Yohei TakedaKunitoshi Imai
Aug 21, 2013·The Analyst·Helma Antony, Patrick M Schaeffer
Jun 29, 2018·Vaccines·Tatsuya YamazakiSachiko Akashi-Takamura
Dec 17, 2019·NPJ Vaccines·Raffael NachbagauerCarine Claeys
Aug 6, 2020·Vaccines·Mrityunjoy BiswasSachiko Akashi-Takamura
Nov 9, 2020·Immunologic Research·Manasik Gumah AliJuan Zhang
Dec 12, 2020·International Immunopharmacology·Hyun Jee HanSan Kim
Jan 23, 2021·Vaccines·Kostlend MaraAndrew G D Bean
Jan 24, 2021·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Cedric HirzelUNKNOWN Influenza in Transplant Study Group
Dec 7, 2018·ACS Infectious Diseases·Tianyu ZhengQun Huo
Sep 27, 2021·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Philippe BuchyEskild Petersen
Oct 24, 2021·Immunology and Cell Biology·Hillary A VandervenStephen J Kent